PEG–PLGA (PEG–poly(lactic-co-glycolic acid)) nanoparticles have demonstrated effectiveness in delivering basic fibroblast growth factor (bFGF) directly to the brain for treatment of Alzheimer’s disease. Here, FGF2 is linked to early-onset autosomal dominant Alzheimer disease.